Limits...
Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68.

Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, Yu YA, Zhang Q, Bullerdiek J, Nolte I, Stritzker J, Szalay AA - J Oncol (2010)

Bottom Line: Therefore, there is an urgent need to identify novel agents for therapy of this disease.Finally, infection with GLV-1h68 led to strong inflammatory and oncolytic effects resulting in significant growth inhibition of the tumors.In summary, the data showed that the GLV-1h68 virus strain has promising potential for effective treatment of canine mammary carcinoma.

View Article: PubMed Central - PubMed

Affiliation: Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA.

ABSTRACT
Canine mammary carcinoma is a highly metastatic tumor that is poorly responsive to available treatment. Therefore, there is an urgent need to identify novel agents for therapy of this disease. Recently, we reported that the oncolytic vaccinia virus GLV-1h68 could be a useful tool for therapy of canine mammary adenoma in vivo. In this study we analyzed the therapeutic effect of GLV-1h68 against canine mammary carcinoma. Cell culture data demonstrated that GLV-1h68 efficiently infected and destroyed cells of the mammary carcinoma cell line MTH52c. Furthermore, after systemic administration, this attenuated vaccinia virus strain primarily replicated in canine tumor xenografts in nude mice. Finally, infection with GLV-1h68 led to strong inflammatory and oncolytic effects resulting in significant growth inhibition of the tumors. In summary, the data showed that the GLV-1h68 virus strain has promising potential for effective treatment of canine mammary carcinoma.

No MeSH data available.


Related in: MedlinePlus

Effect of GLV-1h68 on MTH52c tumor growth in nude mice. (a) MTH52c tumor development in mice after GLV-1h68-treatment versus PBS treatment. Two-way analysis of variance (ANOVA) was used to compare the two corresponding data points of the two groups. P < .05 was considered as statistically significant *P < .05; **P < .01; ***P < .001. (b) Body weights of MTH52c cell xenografted mice after virus treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2902752&req=5

fig6: Effect of GLV-1h68 on MTH52c tumor growth in nude mice. (a) MTH52c tumor development in mice after GLV-1h68-treatment versus PBS treatment. Two-way analysis of variance (ANOVA) was used to compare the two corresponding data points of the two groups. P < .05 was considered as statistically significant *P < .05; **P < .01; ***P < .001. (b) Body weights of MTH52c cell xenografted mice after virus treatment.

Mentions: The therapeutic capacity of GLV-1h68 against an induced canine mammary cancer was tested in 10 female nude mice implanted with MTH52c cells at the age of 6–8 weeks. Twelve days postimplantation, all nude mice developed tumors with sizes between 400 and 500 mm3. Then groups of five tumor-bearing mice were injected with either 5 × 106 pfu of GLV-1h68 or PBS (control). The tumor size of all animals was measured thrice weekly for six weeks. The single vaccinia virus injection caused an efficient inhibition of tumor growth in all GLV-1h68-treated tumor-bearing mice compared to control mice (Figure 6(a)). In addition, no reduction of net body weight of the animals was observed (Figure 6(b)).


Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68.

Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, Yu YA, Zhang Q, Bullerdiek J, Nolte I, Stritzker J, Szalay AA - J Oncol (2010)

Effect of GLV-1h68 on MTH52c tumor growth in nude mice. (a) MTH52c tumor development in mice after GLV-1h68-treatment versus PBS treatment. Two-way analysis of variance (ANOVA) was used to compare the two corresponding data points of the two groups. P < .05 was considered as statistically significant *P < .05; **P < .01; ***P < .001. (b) Body weights of MTH52c cell xenografted mice after virus treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2902752&req=5

fig6: Effect of GLV-1h68 on MTH52c tumor growth in nude mice. (a) MTH52c tumor development in mice after GLV-1h68-treatment versus PBS treatment. Two-way analysis of variance (ANOVA) was used to compare the two corresponding data points of the two groups. P < .05 was considered as statistically significant *P < .05; **P < .01; ***P < .001. (b) Body weights of MTH52c cell xenografted mice after virus treatment.
Mentions: The therapeutic capacity of GLV-1h68 against an induced canine mammary cancer was tested in 10 female nude mice implanted with MTH52c cells at the age of 6–8 weeks. Twelve days postimplantation, all nude mice developed tumors with sizes between 400 and 500 mm3. Then groups of five tumor-bearing mice were injected with either 5 × 106 pfu of GLV-1h68 or PBS (control). The tumor size of all animals was measured thrice weekly for six weeks. The single vaccinia virus injection caused an efficient inhibition of tumor growth in all GLV-1h68-treated tumor-bearing mice compared to control mice (Figure 6(a)). In addition, no reduction of net body weight of the animals was observed (Figure 6(b)).

Bottom Line: Therefore, there is an urgent need to identify novel agents for therapy of this disease.Finally, infection with GLV-1h68 led to strong inflammatory and oncolytic effects resulting in significant growth inhibition of the tumors.In summary, the data showed that the GLV-1h68 virus strain has promising potential for effective treatment of canine mammary carcinoma.

View Article: PubMed Central - PubMed

Affiliation: Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA.

ABSTRACT
Canine mammary carcinoma is a highly metastatic tumor that is poorly responsive to available treatment. Therefore, there is an urgent need to identify novel agents for therapy of this disease. Recently, we reported that the oncolytic vaccinia virus GLV-1h68 could be a useful tool for therapy of canine mammary adenoma in vivo. In this study we analyzed the therapeutic effect of GLV-1h68 against canine mammary carcinoma. Cell culture data demonstrated that GLV-1h68 efficiently infected and destroyed cells of the mammary carcinoma cell line MTH52c. Furthermore, after systemic administration, this attenuated vaccinia virus strain primarily replicated in canine tumor xenografts in nude mice. Finally, infection with GLV-1h68 led to strong inflammatory and oncolytic effects resulting in significant growth inhibition of the tumors. In summary, the data showed that the GLV-1h68 virus strain has promising potential for effective treatment of canine mammary carcinoma.

No MeSH data available.


Related in: MedlinePlus